U.S. Venture Partners related stories
All articles and analysis
Week in deals, Nov. 2, 2009Summary of North American tech companies and other startups that raised venture financing in the past week
- Galleon private portfolio may go on block
Possible sale comes in wake of billionaire found being criminally charged
- peHUB Wire: Monday, October 26, 2009
Survey Time
- peHUB Wire: Monday, October 26, 2009
Survey Time
- Box.net's Unannounced Funding
The company raised another $7.1 million this month from its current investors -- Draper Fisher and U.S. Venture Partners -- but kept mum, allowing the new money to be revealed instead by an SEC filing http://www.sec.gov/Archives/edgar/data/1372612/000137261209000005/xslFormDX01/primary_doc.xml Marketing VP Jen Grant told me it's not a new round, but an extension of the $6 million Series B that Box.net raised nearly two years ago, in January 2008. (There was also a $1.5 million Series A round in 2006). "We decided not to go for a Series C given the economic climate," she said. "It's not the valuation we would want."
- Galleon's Private Portfolio
I wrote about Galleon Management’s $300 million move into venture capital in August 2007 http://www.pewnews.com/story.asp?sectioncode=36&storycode=42657 The firm had hired half a dozen investment professionals and opened an office on Sand Hill Road to invest in private companies looking to go public. Today’s news http://www.reuters.com/article/innovationNews/idUSTRE59K3DF20091021?feedType=RSS&feedName=innovationNews that Galleon decided to wind down its funds after getting $1.3 billion in capital calls (thanks to a pesky insider trading scandal) may close the books on the firm’s operations, but its move out of venture capital happened at least a year before.
- Exit watch, week of Oct. 19, 2009
News summaries of VC-backed companies, such as CopperGate and others, that were bought in the past week
- peHUB Wire: Monday, October 12, 2009
Just Linking Around…
- peHUB Wire: Monday, October 12, 2009
Just Linking Around…
- VC-Backed Proteolix Being Bought For Up To $850 Million
Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) has agreed to acquire Proteolix Inc., a South San Francisco-based drug company focused on protein degradation pathways in cancer and autoimmune diseases. The deal is valued at up to $851 million, including a $276 million up-front cash payment and the remainder in earn-outs. Proteolix has raised around $142 million in VC funding, from firms like U.S. Venture Partners, Advanced Technology Ventures, Latterell Venture Partners, Delphi Ventures, The Vertical Group, Nomura Phase4 Ventures and Westfield Capital Management.